재택 성감염증(STI) 검사 시장 규모, 점유율, 동향 분석 보고서 : 감염증별, 검사 종류별, 검체 종류별, 유통 채널별, 지역별, 부문별 예측(2026-2033년)

At-Home STI Testing Market Summary

The global at-home STI testing market size was estimated at USD 2.98 billion in 2025 and is projected to reach USD 5.86 billion by 2033, growing at a CAGR of 8.85% from 2026 to 2033. The rising prevalence of sexually transmitted infections (STIs) such as chlamydia, gonorrhea, syphilis, and HIV, along with increasing awareness and demand for private, convenient testing solutions, is significantly driving market growth.

According to the World Health Organization, more than 1 million STIs are acquired every day worldwide, while the Centers for Disease Control and Prevention reports over 2.4 million cases of chlamydia, gonorrhea, and syphilis annually in the U.S. If left undiagnosed and untreated, STIs can lead to severe reproductive health complications, infertility, adverse pregnancy outcomes, and increased HIV transmission risk, underscoring the critical need for accessible screening solutions such as at-home STI testing.

The increasing number of regulatory clearances for fully at-home and over-the-counter STI diagnostic solutions is significantly accelerating market adoption. In March 2025, the U.S. Food and Drug Administration granted marketing authorization to Visby Medical's Women's Sexual Health Test, the first fully at-home diagnostic capable of detecting chlamydia, gonorrhea, and trichomoniasis with results in approximately 30 minutes. This milestone marks a major shift toward consumer-operated STI diagnostics, enabling rapid detection without laboratory visits and expanding access to accurate home-based testing.

Advancements in rapid self-testing technologies are further improving accessibility and speed of diagnosis. In October 2025, the FDA approved the INSTI HIV Self-Test from bioLytical Laboratories, a finger-stick blood test delivering results in about one minute, significantly reducing testing barriers and enabling immediate status awareness. In addition, continued availability of oral-fluid rapid tests such as OraQuick supports broader HIV screening uptake through painless, user-friendly self-testing options. These innovations enhance convenience and privacy, further driving consumer adoption.

Technological innovation in molecular and multiplex STI testing is expanding the clinical reliability and scope of home diagnostics. New home-collected molecular tests enable simultaneous detection of multiple infections from a single specimen, improving screening efficiency and patient compliance. For example, multiplex STI testing solutions capable of detecting infections such as chlamydia, gonorrhea, trichomoniasis, and Mycoplasma genitalium from one sample are being deployed through telehealth-enabled care pathways, improving comprehensive sexual health screening and follow-up care. The expansion of multiplex testing is increasing diagnostic accuracy while enhancing the value proposition of at-home screening.

Public health initiatives and digital health distribution programs are also expanding access to home STI testing among high-risk and underserved populations. Programs such as the CDC-supported Together TakeMeHome initiative have distributed hundreds of thousands of free at-home HIV self-tests across the U.S., improving early detection and reaching first-time testers. In parallel, governments and healthcare systems increasingly recognize home testing as a critical strategy to improve screening rates, reduce stigma barriers, and support early treatment. These initiatives are strengthening the role of at-home STI testing in preventive healthcare and disease control strategies.

However, factors such as concerns regarding diagnostic accuracy, improper sample collection, and user interpretation errors can affect test reliability, particularly for self-administered rapid tests, which are anticipated to restrain market growth. Reimbursement limitations and out-of-pocket costs may restrict adoption in price-sensitive markets, especially where public health programs primarily support clinic-based screening. Privacy concerns related to digital result reporting and telehealth integration also continue to influence consumer trust. Furthermore, variability in regulatory frameworks and quality standards across countries creates barriers for manufacturers seeking global expansion.

Global At-home STI Testing Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global at-home STI testing market report based on infection, test type, sample type, distribution channel, and region:

• Infection Outlook (Revenue, USD Million, 2021 - 2033)
• HIV
• Chlamydia (CT)
• Gonorrhea (NG)
• Syphilis
• Trichomoniasis
• HPV
• Hepatitis B & C
• Others
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• Rapid Lateral Flow Immunoassays
• Molecular / NAAT-based Kits
• Multiplex Panel Testing
• Others
• Sample Type Outlook (Revenue, USD Million, 2021 - 2033)
• Blood
• Urine
• Oral Fluid/Saliva
• Vaginal Swab
• Others
• Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
• Online Pharmacies & D2C Platforms
• Retail Pharmacies
• Public Health Distribution Programs
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Norway
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Segment Definitions
  • 1.2.1. Infection
  • 1.2.2. Test Type
  • 1.2.3. Sample Type
  • 1.2.4. Distribution Channel
  • 1.2.5. Regional Scope
  • 1.2.6. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Regional outlook
• 2.4. Competitive Insights

Chapter 3. At-home STI Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising global prevalence of sexually transmitted infections (STIs)
    • 3.2.1.2. Increasing adoption of telehealth and digital sexual health services
    • 3.2.1.3. Growing demand for private, convenient, and stigma-free testing solutions
    • 3.2.1.4. Regulatory approvals and technological advancements in self-testing diagnostics
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Concerns regarding test accuracy and improper sample collection
    • 3.2.2.2. Limited reimbursement coverage and affordability constraints in emerging markets
• 3.3. At-home STI Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of suppliers
    • 3.3.1.2. Bargaining power of buyers
    • 3.3.1.3. Threat of substitutes
    • 3.3.1.4. Threat of new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic landscape
    • 3.3.2.3. Social landscape
    • 3.3.2.4. Technological landscape
    • 3.3.2.5. Environmental landscape
    • 3.3.2.6. Legal landscape

Chapter 4. At-home STI Testing Market: Infection Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. At-home STI Testing Market: Infection Movement Analysis
• 4.3. At-home STI Testing Market by Infection Outlook (USD Million)
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 4.5. HIV
  • 4.5.1. HIV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.6. Chlamydia (CT)
  • 4.6.1. Chlamydia (CT) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.7. Gonorrhea (NG)
  • 4.7.1. Gonorrhea (NG) Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.8. Syphilis
  • 4.8.1. Syphilis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.9. Trichomoniasis
  • 4.9.1. Trichomoniasis Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.10. HPV
  • 4.10.1. HPV Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.11. Hepatitis B & C
  • 4.11.1. Hepatitis B & C Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.12. Others
  • 4.12.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. At-home STI Testing Market: Test Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. At-home STI Testing Market: Test Type Movement Analysis
• 5.3. At-home STI Testing Market by Test Type Outlook (USD Million)
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 5.5. Rapid Lateral Flow Immunoassays
  • 5.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Molecular / NAAT-based Kits
  • 5.6.1. Molecular / NAAT-based Kits Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. Multiplex Panel Testing
  • 5.7.1. Multiplex Panel Testing Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. At-home STI Testing Market: Sample Type Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. At-home STI Testing Market: Sample Type Movement Analysis
• 6.3. At-home STI Testing Market by Sample Type Outlook (USD Million)
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 6.5. Blood
  • 6.5.1. Blood Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.6. Urine
  • 6.6.1. Urine Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.7. Oral Fluid/Saliva
  • 6.7.1. Oral Fluid/Saliva Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.8. Vaginal Swab
  • 6.8.1. Vaginal Swab Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 6.9. Others
  • 6.9.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. At-home STI Testing Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. At-home STI Testing Market: Distribution Channel Movement Analysis
• 7.3. At-home STI Testing Market by Distribution Channel Outlook (USD Million)
• 7.4. Market Size & Forecasts and Trend Analyses, 2021 - 2033 for the following
• 7.5. Online Pharmacies & D2C Platforms
  • 7.5.1. Online Pharmacies & D2C Platforms Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.6. Retail Pharmacies
  • 7.6.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.7. Public Health Distribution Programs
  • 7.7.1. Public Health Distribution Programs Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
• 7.8. Others
  • 7.8.1. Others Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. At-home STI Testing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Dashboard
• 8.2. Market Size, & Forecasts Trend Analysis, 2021 - 2033:
• 8.3. North America
  • 8.3.1. U.S.
    • 8.3.1.1. Key country dynamics
    • 8.3.1.2. Regulatory framework/ reimbursement structure
    • 8.3.1.3. Competitive scenario
    • 8.3.1.4. U.S. market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.2. Canada
    • 8.3.2.1. Key country dynamics
    • 8.3.2.2. Regulatory framework/ reimbursement structure
    • 8.3.2.3. Competitive scenario
    • 8.3.2.4. Canada market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.3.3. Mexico
    • 8.3.3.1. Key country dynamics
    • 8.3.3.2. Regulatory framework/ reimbursement structure
    • 8.3.3.3. Competitive scenario
    • 8.3.3.4. Mexico market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.4. Europe
  • 8.4.1. UK
    • 8.4.1.1. Key country dynamics
    • 8.4.1.2. Regulatory framework/ reimbursement structure
    • 8.4.1.3. Competitive scenario
    • 8.4.1.4. UK market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.2. Germany
    • 8.4.2.1. Key country dynamics
    • 8.4.2.2. Regulatory framework/ reimbursement structure
    • 8.4.2.3. Competitive scenario
    • 8.4.2.4. Germany market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.3. France
    • 8.4.3.1. Key country dynamics
    • 8.4.3.2. Regulatory framework/ reimbursement structure
    • 8.4.3.3. Competitive scenario
    • 8.4.3.4. France market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.4. Italy
    • 8.4.4.1. Key country dynamics
    • 8.4.4.2. Regulatory framework/ reimbursement structure
    • 8.4.4.3. Competitive scenario
    • 8.4.4.4. Italy market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.5. Spain
    • 8.4.5.1. Key country dynamics
    • 8.4.5.2. Regulatory framework/ reimbursement structure
    • 8.4.5.3. Competitive scenario
    • 8.4.5.4. Spain market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.6. Norway
    • 8.4.6.1. Key country dynamics
    • 8.4.6.2. Regulatory framework/ reimbursement structure
    • 8.4.6.3. Competitive scenario
    • 8.4.6.4. Norway market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.7. Sweden
    • 8.4.7.1. Key country dynamics
    • 8.4.7.2. Regulatory framework/ reimbursement structure
    • 8.4.7.3. Competitive scenario
    • 8.4.7.4. Sweden market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.4.8. Denmark
    • 8.4.8.1. Key country dynamics
    • 8.4.8.2. Regulatory framework/ reimbursement structure
    • 8.4.8.3. Competitive scenario
    • 8.4.8.4. Denmark market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.5. Asia Pacific
  • 8.5.1. Japan
    • 8.5.1.1. Key country dynamics
    • 8.5.1.2. Regulatory framework/ reimbursement structure
    • 8.5.1.3. Competitive scenario
    • 8.5.1.4. Japan market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.2. China
    • 8.5.2.1. Key country dynamics
    • 8.5.2.2. Regulatory framework/ reimbursement structure
    • 8.5.2.3. Competitive scenario
    • 8.5.2.4. China market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.3. India
    • 8.5.3.1. Key country dynamics
    • 8.5.3.2. Regulatory framework/ reimbursement structure
    • 8.5.3.3. Competitive scenario
    • 8.5.3.4. India market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.4. Australia
    • 8.5.4.1. Key country dynamics
    • 8.5.4.2. Regulatory framework/ reimbursement structure
    • 8.5.4.3. Competitive scenario
    • 8.5.4.4. Australia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.5. South Korea
    • 8.5.5.1. Key country dynamics
    • 8.5.5.2. Regulatory framework/ reimbursement structure
    • 8.5.5.3. Competitive scenario
    • 8.5.5.4. South Korea market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.5.6. Thailand
    • 8.5.6.1. Key country dynamics
    • 8.5.6.2. Regulatory framework/ reimbursement structure
    • 8.5.6.3. Competitive scenario
    • 8.5.6.4. Thailand market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.6. Latin America
  • 8.6.1. Brazil
    • 8.6.1.1. Key country dynamics
    • 8.6.1.2. Regulatory framework/ reimbursement structure
    • 8.6.1.3. Competitive scenario
    • 8.6.1.4. Brazil market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.6.2. Argentina
    • 8.6.2.1. Key country dynamics
    • 8.6.2.2. Regulatory framework/ reimbursement structure
    • 8.6.2.3. Competitive scenario
    • 8.6.2.4. Argentina market estimates and forecasts, 2021 - 2033 (USD Million)
• 8.7. MEA
  • 8.7.1. South Africa
    • 8.7.1.1. Key country dynamics
    • 8.7.1.2. Regulatory framework/ reimbursement structure
    • 8.7.1.3. Competitive scenario
    • 8.7.1.4. South Africa market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.2. Saudi Arabia
    • 8.7.2.1. Key country dynamics
    • 8.7.2.2. Regulatory framework/ reimbursement structure
    • 8.7.2.3. Competitive scenario
    • 8.7.2.4. Saudi Arabia market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.3. UAE
    • 8.7.3.1. Key country dynamics
    • 8.7.3.2. Regulatory framework/ reimbursement structure
    • 8.7.3.3. Competitive scenario
    • 8.7.3.4. UAE market estimates and forecasts, 2021 - 2033 (USD Million)
  • 8.7.4. Kuwait
    • 8.7.4.1. Key country dynamics
    • 8.7.4.2. Regulatory framework/ reimbursement structure
    • 8.7.4.3. Competitive scenario
    • 8.7.4.4. Kuwait market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Recent Developments & Impact Analysis by Key Market Participants
• 9.3. Company Market Share Analysis, 2025
• 9.4. Key Company Profiles
  • 9.4.1. OraSure Technologies Inc.
    • 9.4.1.1. Company overview
    • 9.4.1.2. Financial performance
    • 9.4.1.3. Product benchmarking
    • 9.4.1.4. Strategic initiatives
  • 9.4.2. Abbott
    • 9.4.2.1. Company overview
    • 9.4.2.2. Financial performance
    • 9.4.2.3. Product benchmarking
    • 9.4.2.4. Strategic initiatives
  • 9.4.3. bioLytical Laboratories Inc.
    • 9.4.3.1. Company overview
    • 9.4.3.2. Financial performance
    • 9.4.3.3. Product benchmarking
    • 9.4.3.4. Strategic initiatives
  • 9.4.4. Chembio Diagnostics, Inc.
    • 9.4.4.1. Company overview
    • 9.4.4.2. Financial performance
    • 9.4.4.3. Product benchmarking
    • 9.4.4.4. Strategic initiatives
  • 9.4.5. BD (Becton Dickinson)
    • 9.4.5.1. Company overview
    • 9.4.5.2. Financial performance
    • 9.4.5.3. Product benchmarking
    • 9.4.5.4. Strategic initiatives
  • 9.4.6. LetsGetChecked
    • 9.4.6.1. Company overview
    • 9.4.6.2. Financial performance
    • 9.4.6.3. Product benchmarking
    • 9.4.6.4. Strategic initiatives
  • 9.4.7. Everlywell
    • 9.4.7.1. Company overview
    • 9.4.7.2. Financial performance
    • 9.4.7.3. Product benchmarking
    • 9.4.7.4. Strategic initiatives
  • 9.4.8. NURX Inc.
    • 9.4.8.1. Company overview
    • 9.4.8.2. Financial performance
    • 9.4.8.3. Product benchmarking
    • 9.4.8.4. Strategic initiatives
  • 9.4.9. Hologic, Inc.
    • 9.4.9.1. Company overview
    • 9.4.9.2. Financial performance
    • 9.4.9.3. Product benchmarking
    • 9.4.9.4. Strategic initiatives